CGTX vs. ATRA, ELUT, PASG, PLX, GRTS, DTIL, ALVR, TIL, ATHA, and CVM
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Atara Biotherapeutics (ATRA), Elutia (ELUT), Passage Bio (PASG), Protalix BioTherapeutics (PLX), Gritstone bio (GRTS), Precision BioSciences (DTIL), AlloVir (ALVR), Instil Bio (TIL), Athira Pharma (ATHA), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
Atara Biotherapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
Atara Biotherapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 4,419.04%. Cognition Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 183.69%. Given Cognition Therapeutics' higher probable upside, equities research analysts plainly believe Atara Biotherapeutics is more favorable than Cognition Therapeutics.
Cognition Therapeutics has lower revenue, but higher earnings than Atara Biotherapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics received 421 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 67.56% of users gave Atara Biotherapeutics an outperform vote while only 53.33% of users gave Cognition Therapeutics an outperform vote.
Cognition Therapeutics has a net margin of 0.00% compared to Cognition Therapeutics' net margin of -671.70%. Atara Biotherapeutics' return on equity of -98.65% beat Cognition Therapeutics' return on equity.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Atara Biotherapeutics had 14 more articles in the media than Cognition Therapeutics. MarketBeat recorded 16 mentions for Atara Biotherapeutics and 2 mentions for Cognition Therapeutics. Atara Biotherapeutics' average media sentiment score of 1.31 beat Cognition Therapeutics' score of 1.02 indicating that Cognition Therapeutics is being referred to more favorably in the news media.
Summary
Cognition Therapeutics beats Atara Biotherapeutics on 10 of the 17 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
